| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 134, 395-404, Copyright © 1989 by American Society for Investigative Pathology
REGULAR ARTICLES |
T Doi, LJ Striker, SJ Elliot, FG Conti and GE Striker
Renal Cell Biology Group, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892.
Mesangial cell hyperplasia is a feature common to several human glomerular diseases. The cause of this increased cell number is unknown. The authors assessed human mesangial cells in vitro and found that they possessed an insulinlike growth factor-1 (IGF-1) receptor consisting of alpha and beta units (Mr, 130 k and 90 k respectively). Fifty percent inhibition of IGF-1 specific binding to the receptor required 1 X 10(-9) M IGF-1, greater than 1 X 10(-6) M insulin and 1 X 10(-7) M multiplication stimulating activity (MSA). Analysis of binding by the method of Scatchard revealed one type of IGF-1 receptor with a Kd of 1.35 X 10(-9) M, and a number per cell of 1.04 X 10(5). Binding studies on whole glomeruli had similar specificity and there were 7.17 X 10(7) receptors per glomerulus (Kd, 1.12 X 10(-9) M). Examination of the effect of IGF-1 on the cell cycle revealed that exposure of cells to both IGF-1 and platelet-derived growth factor (PDGF) led to a significant increase in 3H-thymidine incorporation into cell layers. Antibody to PDGF abolished only that response due to PDGF. Similarly, the labeling index of cells pretreated with PDGF, washed, and then exposed to IGF-1 was increased, whereas if the order of ligand exposure was reversed, there was no such additive effect. Finally, PDGF increased RNA and protein synthesis, and this response was not enhanced by IGF-1. In summary, human mesangial cells and whole glomeruli possess IGF-1-specific receptors and IGF-1 was found to act as a progression factor in the cell cycle.
This article has been cited by other articles:
 |
|
 |
|
  B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zheng, F. Cornacchia, I. Schulman, A. Banerjee, Q.-l. Cheng, M. Potier, A. R. Plati, M. Berho, S. J. Elliot, J. Li, et al. Development of Albuminuria and Glomerular Lesions in Normoglycemic B6 Recipients of db/db Mice Bone Marrow: The Role of Mesangial Cell Progenitors Diabetes, September 1, 2004; 53(9): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cellier, M. Mage, J. Duchene, C. Pecher, R. Couture, J.-L. Bascands, and J.-P. Girolami Bradykinin reduces growth factor-induced glomerular ERK1/2 phosphorylation Am J Physiol Renal Physiol, February 1, 2003; 284(2): F282 - F292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Marsh, K. J. Gibson, J. Wu, P. C. Owens, J. A. Owens, and E. R. Lumbers Chronic effect of insulin-like growth factor I on renin synthesis, secretion, and renal function in fetal sheep Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R318 - R326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Abe, N. Iehara, K. Utsunomiya, T. Kita, and T. Doi A Vitamin D Analog Regulates Mesangial Cell Smooth Muscle Phenotypes in a Transforming Growth Factor-beta Type II Receptor-mediated Manner J. Biol. Chem., July 23, 1999; 274(30): 20874 - 20878. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
